The Institute of Clinical Research invites applications for its one-year, part-time Post-graduate Diploma in Clinical Research.
The study, which was conducted on more than 100 healthcare workers at three centres in India including Sir Ganga Ram Hospital, found that the B.1.617.2 Delta variant not only dominates vaccine-breakthrough infections with higher respiratory viral loads compared to non-Delta infections (Ct value of 16.5 versus 19) but also generates greater transmission among the fully vaccinated HCWs.
The South African authorities said the detected cases and percentage of people testing positive are both increasing quickly, particularly in particularly in most populated province of Gauteng, North West and Limpopo regions of the country.
This year, India's Prime Minister Narendra Modi, Bollywood actor Ayushmann Khurrana, the 'dadi from Shaheen Bhagh' Bilkis, Alphabet and Google CEO Sundar Pichai and Professor Ravindra Gupta are among TIME's 100 most influential people of 2020.
'We believe that India is capable of producing the Gamaleya vaccine and it is very important to say that those partnerships to produce the vaccine will enable us to cover the demand that we have'
rediffGURU Mayank Chandel offers advice to students interested in a careers in science or engineering after class 10 and 12.
'This virus may have more immune evasion capability and therefore, it may make you more sick.'
According to government sources, the matter was discussed by the national expert group on vaccine administration for COVID-19 in its last meeting held on August 22.
'Just put a patch on your arm and the vaccine can be absorbed by the body.'
Once available, Sputnik V will be the third vaccine to be used in India against coronavirus.
Dr V K Paul, Member (Health) Niti Aayog, who also chairs the national expert group on COVID-19 vaccine administration, said the government attaches 'great importance to this offer of partnership from a very special friend to this nation'.
The reduced severity of the Omicron variant is good news for now, but it is the result of an 'evolutionary mistake' and does not indicate that the virus which causes COVID-19 is becoming less virulent, a leading Indian-origin scientist from the University of Cambridge warned on Thursday.
The Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India, RDIF and Dr Reddy's said in a joint statement.
'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).
The reduced severity of Omicron is good news for now, but it is the result of an "evolutionary mistake" as Covid-19 is transmitting very efficiently and there is no reason for it to become milder, indicating that the next variant could be more virulent, a leading Indian-origin scientist from the University of Cambridge has warned.
'The only idea -- the only idea -- of the shutdown was to buy time.'
Nobel laureate Peter Doherty says his 'big worry' is there could be refusals for other vaccines if doubts over its safety turn out to be true.
The first phase of the programme will kick off with vaccinations in Hyderabad on Monday and in Visakhapatnam on Tuesday (May 18) at Apollo facilities.
As worries over India's COVID-19 spike mount -- the country added 75,809 cases on Tuesday to take its tally to 42,80,422 -- scientists are grappling with the pivotal issue of antibodies and trying to understand how they impact on the progression of the disease.
Women are great team players and collaborators, 'but they don't put themselves forward,' Dr Gagandeep Kang, the first Indian woman scientist to be elected as a Fellow of the Royal Society, tells Veenu Sandhu.
Sputnik V is the third vaccine India has given the go-ahead to after 'Covishield', developed by Oxford University and AstraZeneca and 'Covaxin', the indigenous vaccine manufactured by Bharat Biotech. Covishield is manufactured by the Serum Institute of India.
By 2022, there is a plan to make an mRNA-technology vaccine, for which it has tied up with Canadian firm Providence Therapeutics.
'The most intriguing thing (about COVID-19) is the range of the illness -- from asymptomatic or less symptoms to death and quite severe manifestations.' 'The vaccine will be at least another year away from having any effect.'
While Bharat Biotech's Covaxin is in trials among children already, Serum Institute of India will begin Novavax vaccine trials on children from July, whereas the Pfizer vaccine has been approved for adolescents in the United States; and Cadila Healthcare's ZyCoV-D has done trials on 12 year-olds and above already, reports Sohini Das.
While some researchers are developing prototypes for ventilators to overcome their shortage, others have teamed up to develop testing kits.
'He came back from the US only to work for his country.' 'He has invested his fortunes to build this company and is married to his work.' 'Rarely does one see such commitment.'
The government is hopeful of a speedy launch of single-dose COVID-19 vaccine Sputnik Light in India and all stakeholders, including the Russian manufacturer and its Indian partners, have been directed to fast-track the application and regulatory approval procedures for the jab to boost the country's vaccination drive, sources said.
In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
'Almost 70 per cent production time of a vaccine is dedicated to quality control, which is done through several hundred tests.'
'Some of the longer-term implications of COVID-19 are not related to the virus itself.' 'They are actually related to immune responses from the virus.'
The Australian immunologist, who cautioned that the number of COVID-19 cases will rise in the coming days, said the earliest time frame for an effective vaccine 'going into large numbers of people' is nine to 12 months.
'You can still acquire the COVID-19 virus even if you are vaccinated.' 'But if you develop the disease, (after being vaccinated) the likelihood is that it will be mild.' 'It just makes sense to continue to take precautions, because you may be around a lot of unvaccinated people.'
A virologist answers questions on the deadly virus presently haunting the world.
'Essentially there are three things the government should be doing: Identify who you are going to get your vaccine from, figure out how you are going to pay for it, and figure out how you're going to deliver it and to whom.'
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances